Table of Contents

Th1 Spectrum Disorder

Th1 Spectrum DisorderThe overlap of different disease symptoms in different patients with similar diagnoses - caused by the fact that any one bacterial species can contribute to numerous disease states. refers to the group of chronic inflammatory diseases, which are hypothesized to be caused by the Th1 pathogens, a microbiota of bacteria which include L-form, biofilm, and intracellular bacterial forms. Although the exact species and forms of bacteria, as well as the location and extent of the infection, vary between one patient suffering from chronic disease and the next, the disease process is common: bacterial pathogens persist and reproduce by disabling the innate immune response.

Although patients who become infected with the Th1 pathogens are given a variety of diagnoses, there are often no clear cut distinctions between one disease and the next. Rather, symptoms frequently overlap creating a spectrum of illness in which diseases are more connected to one another than mutually exclusive disease states.

The evidence that chronic disease is ultimately a spectrum disorder with a common cause includes:

Conflict in theories

Traditionally, diseases are understood to be discrete and have their own respective and distinct pathologies. This theory of disease has been advanced by researchers intent upon pinpointing the human genes which they theorize cause disease. The existence of a vast network of clinical specialists and sub-specialists only reinforces this idea.

According to the Marshall Pathogenesis, a range of chronic diseases is caused by a common etiology or disease process. Patients accumulate Th1 pathogens, which proliferate by disabling the Vitamin D Receptor and consequently weakening the innate immune response.

Comorbidity of inflammatory diseases

One of the striking features of a variety of neuropsychiatric diseases (e.g., affective disorders) is their variance, with differences observed across individuals in terms of their susceptibility, in the combination of systems that are disturbed, and in the therapeutic and adverse responses to various medications…. The microbiome [may represent] a source of this observed variance.

A. Gonzalez et al.1)

When the Th1 pathogens compromise the immune response, they make it easier for other types of bacteria in other locations to infect the body as well. This phenomenon is known as comorbidity. Although a comorbid condition is traditionally understood to be unrelated to the underlying condition, the sheer number of common comorbidities points to a common pathology. Indeed, a 2012 Dutch analysis of patients showed that disease pairs occurred more frequently than would be expected if diseases had been independent.2)

Epidemiological research may have its share of liabilities, but one contribution it has made is in demonstrating the strong connections between seemingly disparate diseases as evidenced by the number of patients who share diagnoses with two or more “unrelated” disease processes.

The following wheel shows how truly related chronic diseases are. Each “spoke” represents a published study which has demonstrated a significant statistical relationship between patients suffering from one disease and the next.

The following paragraph contains links to all the studies alluded to in the above chart.

Please note that some of the disease names in the following paragraph are links to articles discussing those diseases in further detail.

allergies 3) alopecia areata 4) 5) Alzheimer's disease & dementia 6) 7) ankylosing spondylitis 8) 9) 10) anorexia nervosa 11) anxiety disorders 12) 13) 14) 15) 16) 17) 18) 19) 20) arthritis 21) 22) 23) 24) 25) 26) 27) asthma 28) 29) 30) 31) 32) 33) 34) 35) 36) 37) 38) 39) bipolar disease 40) 41) 42) 43) cancer 44) 45) 46) 47) cardiac disease 48) 49) 50) 51) 52) 53) 54) 55) 56) 57) cardiovascular disease 58) 59) 60) 61) 62) celiac disease 63) 64) 65) 66) chronic fatigue syndrome 67) 68) 69) chronic obstructive pulmonary disease 70) depression 71) 72) 73) 74) 75) 76) 77) 78) 79) 80) 81) 82) 83) 84) 85) 86) 87) diabetes 88) 89) 90) 91) 92) 93) 94) diabetes, type1 95) 96) 97) diabetes, type2 98) fibromyalgia 99) 100) Guillain-Barré syndrome 101) 102) hypertension 103) 104) inflammatory bowel disease (Crohn's disease and ulcerative colitis) 105) 106) 107) 108) 109) 110) 111) 112) 113) 114) 115) 116) 117) 118) lupus 119) 120) 121) 122) 123) multiple chemical sensitivity 124) multiple sclerosis 125) 126) 127) 128) 129) 130) 131) myasthenia gravis 132) obesity 133) 134) 135) 136) 137) obsessive compulsive disorder 138) 139) 140) 141) 142) osteoporosis 143) 144) 145) 146) Parkinson's disease 147) 148) 149) 150) periodontal disease 151) 152) pernicious anemia 153) psoriasis 154) 155) 156) 157) 158) rheumatoid arthritis 159) 160) 161) sarcoidosis 162) 163) schizophrenia 164) 165) 166) scleroderma 167) Sjogren's syndrome 168) 169) 170) 171) thyroiditis (Graves' disease and Hashimoto's thyroiditis) 172) 173) 174) 175) 176) 177) 178) uveitis 179) 180) vitiligo 181)

Multimorbidity

25% of Americans have more than one chronic condition.

According to a 2012 JAMA paper, the most common chronic condition experienced by adults is multimorbidity, the coexistence of multiple chronic diseases or conditions.182) In patients with coronary disease, for example, it is the sole condition in only 17% of cases.183) Almost 3 in 4 individuals aged 65 years and older have multiple chronic conditions, as do 1 in 4 adults younger than 65 years who receive health care.184) Adults with multiple chronic conditions are the major users of health care services at all adult ages, and account for more than two-thirds of health care spending.185)

To control for confounding variables, researchers often exclude patients with more than one condition from research studies even though they represent the majority of patients.186) Jeste et al made this observation in patients with schizophrenia187) and there's no reason to think it's any different with other patient groups.

A recent survey of Marshall Protocol patients, discussed in Amy Proal's presentation at Congress on Autoimmunity, showed that of those with Hashimoto's thyroiditis, only 8% had been diagnosed with Hashimoto's alone.

Metabolic syndrome

Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components 188)

Intestinal barrier

Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. 189)

The two major triggers of zonulin release that have been described so far are bacteria and gliadin. It is well described that many enteric pathogens are able to produce enterotoxins that affect the intestinal tight junction of the host. 190)

The challenge of diagnosing diseases caused by bacteria

Many doctors are reluctant to say that chronic diseases are caused by bacterial pathogens and for a couple of reasons.

No consistent symptom presentation

Medicine has difficulty diagnosing disorders where there is no consistently identified anatomic abnormality or documented metabolic/physiological dysfunction.191)

Diagnoses are driven by perceived therapeutic options

What a clinician thinks causes many of the ill-defined chronic diseases may in fact be shaped by available treatment options for that disease.

Consider dentists. Most dentists will readily concede that bacteria cause plaque and tooth decay. The fact that a dentist can employ a therapy against plaque (in this case, manually removing plaque) clearly shapes their opinion about the etiology of the disease. That the intervention is at least temporarily effective also has something to do with it, but perhaps not as much as most people might imagine.

When it comes to lethargy or exercise intolerance or difficulty breathing or any number of other symptoms of disease, the explanation for the disease's etiology is often driven by the available mainstream treatment options, of which very few are effective. These options are themselves highly influenced by pharmaceutical companies which have a vested interest in selling a drug or treatment. In their drive to differentiate themselves and their product, these companies will overemphasize the distinctions among diseases when there may be no such fundamental differences.

False assurance of diagnostic compartmentalization

Another challenge relates to how diseases are segmented into categories even when the nature of the diseases themselves don't warrant such fine-graded distinctions.

One who pores through the articles of a medical textbook could easily form the impression that diseases are discrete, well-defined and mutually exclusive. The reality is that the nature of illness is such that diagnosis is often inexact. Over the past few decades, the sensitivity and specificity of diagnostic tests has, in many cases, increased dramatically. Yet, neither precision nor accuracy is useful when two test results for a patient suggest conflicting diagnoses.

To resolve this ambiguity, epidemiologists have developed a kind of stop-gap measure: rubrics - many of them “evidence-based” - for diagnosing disease. A rubric is a checklist of sorts. Doctors who diagnose according to a rubric look to see if a patient has at least a certain number of classical symptoms - say, eight of the twelve symptoms listed. Given that the vagaries of any one chronic disease are determined by patients' unique pea soup, that is, their particular mix of Th1 pathogens, the traditional methods for diagnosis leave something to be desired.

Patients presenting with prototypical cases of a given disease tend to be the exception rather than the rule. They may have some of the classical symptoms of a given disease but not others. Also, patients may have symptoms that are unique to a different disease. Patients with symptoms of chronic disease could present five different doctors with the same set of symptoms and get five different diagnoses, and many have!

Excessive testing

In the face of uncertainty and ambiguity, a clinician's natural response might be to order a battery of tests. After all, the more information clinicians obtain, the more confidence they have in the validity of their diagnoses, even when such confidence may not be justified on the basis of the information obtained.

In his paper, “Our stubborn quest for diagnostic certainty: a cause of excessive testing,” JP Kassirer writes:

Absolute certainty in diagnosis is unattainable, no matter how much information we gather, how many observations we make, or how many tests we perform. Our task is not to attain certainty, but rather to reduce the level of diagnostic uncertainty enough to make optimal therapeutic decisions…. We continue to test excessively, partly because of our discomfort with uncertainty.

Jerome Kassirer, MD 192)

In practice, as one approaches diagnostic certainty the useful information returned by diagnostic tests and observations approaches zero.193)

A 2011 article in the Daily Beast showed how some common tests and procedures may do more harm than good.

A single diagnosis for chronic inflammatory disease

Given that all of the so-called autoimmune diseases and chronic infections are a variation of the Th1 inflammatory process, neither a specific diagnostic label or identification of specific pathogens is needed to begin the Marshall Protocol (MP). With the MP, patients identify Th1 inflammation with simple blood tests and then confirm the presence of occult microbes with a therapeutic probe. As treatment continues, the presence of the immune system reactions confirms the continuing efficacy of treatment. And finally, symptom resolution, absence of immune system reactions and normal blood work indicate recovery.

Where the MP is unique is that I set out to kill pathogens which have never been fully identified, whose exact nature is still largely unknown. I did this based on an understanding of the pathogens' biochemical effects on the body, and the consequent understanding of how they must therefore be exerting that effect…. We have focused on the commonalities, rather than the differences, between immune disease syndromes, and this tends to make it easier to distinguish the forest from the trees.

Trevor Marshall, PhD

A corollary of this principle is that attempts to compare one patient's disease with another's may be futile. Certainly there is a great deal of variability in the location and severity of infection and the corresponding symptoms, but ultimately there is no fundamental difference between the origin of patients' disease states and there is, therefore, no significant difference in their ultimate recovery trajectories.

Health and disease is a continuum

Related article: Th1 Spectrum Disorder

…because the women are all healthy when they enroll [then any disease can be detected as they continue sampling from that time].

Claire Fraser-Liggett, Director of the Institute for Genome Sciences at the University of Maryland, BBC Radio 4 program about the Human Microbiome

It is common practice to assign one group of patients participating in a controlled trial to be the “healthy control group.” While researchers are apt to make a hard distinction between health and disease, this dichotomy is contrary to what we know about successive infection.

The process of successive infection does not just occur in sick people or people who are symptomatic. In healthy subjects, subclinical infection is not the exception, but the rule. For example:

  • 30% of healthy people are carriers of the pathogen Staphylococcus aureus.194)
  • A 2011 pyrosequencing study looked at 16S rDNA amplicons of eight culture-negative healthy female urine specimens.195) The study found a significant amount of sequences belonging to bacteria with a known pathogenic potential.

From even before birth, every human is constantly acquiring new microbes as demonstrated in several studies196) by Rob Knight and Jeffrey Gordon's team. After sequencing the microbiome of two individuals at four body sites over 396 timepoints, the group essentially concluded that the notion of a “core microbiome” is overblown.

We find that despite stable differences between body sites and individuals, there is pronounced variability in an individual's microbiota across months, weeks and even days. Additionally, only a small fraction of the total taxa found within a single body site appear to be present across all time points, suggesting that no core temporal microbiome exists at high abundance (although some microbes may be present but drop below the detection threshold). Many more taxa appear to be persistent but non-permanent community members.

J. Gregory Caporaso et al. 197)

Clearly, the microbiota can be affected in any number of ways that are not picked up by the relatively crude tests that we use to measure “health.” Further, patients will carry pathogenic elements of their microbiota without symptoms to show for it – at least initially.

The variability of patients' responses – both between control and experimental groups, and among an experimental group (some subjects get a side effect, some don't) – may ultimately be a testament to the unique nature of each person's microbiota.

Because everyone person's microbiota is unique, it may be overly simplistic, if not naive, to say there is such a thing as a person who is truly healthy.

1)
Gonzalez A, Stombaugh J, Lozupone C, Turnbaugh PJ, Gordon JI, Knight R. The mind-body-microbial continuum. Dialogues Clin Neurosci. 2011;13(1):55-62. doi: 10.31887/DCNS.2011.13.1/agonzalez.
[PMID: 21485746] [PMCID: 3139398] [DOI: 10.31887/DCNS.2011.13.1/agonzalez]
2) , 186)
van Oostrom SH, Picavet HSJ, van Gelder BM, Lemmens LC, Hoeymans N, van Dijk CE, Verheij RA, Schellevis FG, Baan CA. Multimorbidity and comorbidity in the Dutch population - data from general practices. BMC Public Health. 2012 Aug 30;12:715. doi: 10.1186/1471-2458-12-715.
[PMID: 22935268] [PMCID: 3490727] [DOI: 10.1186/1471-2458-12-715]
3) , 28) , 95) , 172)
Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol. 1997 Feb;99(2):S773-80. doi: 10.1016/s0091-6749(97)70126-x.
[PMID: 9042070] [DOI: 10.1016/s0091-6749(97)70126-x]
4) , 17) , 73)
Koo JY, Shellow WV, Hallman CP, Edwards JE. Alopecia areata and increased prevalence of psychiatric disorders. Int J Dermatol. 1994 Dec;33(12):849-50. doi: 10.1111/j.1365-4362.1994.tb01018.x.
[PMID: 7883407] [DOI: 10.1111/j.1365-4362.1994.tb01018.x]
5) , 66) , 69) , 97) , 102) , 118) , 123) , 131) , 132) , 153) , 158) , 161) , 167) , 171) , 178) , 181)
Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007 Aug;29(1):1-9. doi: 10.1016/j.jaut.2007.05.002. Epub 2007 Jun 19.
[PMID: 17582741] [PMCID: 2717015] [DOI: 10.1016/j.jaut.2007.05.002]
6) , 80)
Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry. 1999 Sep;14(9):711-8.
[PMID: 10479741]
7) , 133)
Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008 Sep 30;71(14):1057-64. doi: 10.1212/01.wnl.0000306313.89165.ef. Epub 2008 Mar 26.
[PMID: 18367704] [DOI: 10.1212/01.wnl.0000306313.89165.ef]
8) , 22) , 58) , 160)
Han C, Robinson DWJ, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006 Nov;33(11):2167-72. Epub 2006 Sep 1.
[PMID: 16981296]
9) , 24) , 113) , 179)
Loftus EVJ. Inflammatory bowel disease extending its reach. Gastroenterology. 2005 Sep;129(3):1117-20. doi: 10.1053/j.gastro.2005.07.042.
[PMID: 16143148] [DOI: 10.1053/j.gastro.2005.07.042]
10) , 163)
Sezer I, Melikoglu MA, Cay HF, Kocabas H, Kacar C. A co-occurrence of sarcoidosis and ankylosing spondylitis: a case report. Rheumatol Int. 2008 Apr;28(6):605-7. doi: 10.1007/s00296-007-0483-6. Epub 2007 Nov 16.
[PMID: 18008072] [DOI: 10.1007/s00296-007-0483-6]
11) , 16) , 142)
Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry. 2004 Dec;161(12):2215-21. doi: 10.1176/appi.ajp.161.12.2215.
[PMID: 15569892] [DOI: 10.1176/appi.ajp.161.12.2215]
12) , 139)
Lensi P, Cassano GB, Correddu G, Ravagli S, Kunovac JL, Akiskal HS. Obsessive-compulsive disorder. Familial-developmental history, symptomatology, comorbidity and course with special reference to gender-related differences. Br J Psychiatry. 1996 Jul;169(1):101-7. doi: 10.1192/bjp.169.1.101.
[PMID: 8818377] [DOI: 10.1192/bjp.169.1.101]
13) , 14) , 41) , 42) , 71) , 162)
Goracci A, Fagiolini A, Martinucci M, Calossi S, Rossi S, Santomauro T, Mazzi A, Penza F, Fossi A, Bargagli E, Pieroni MG, Rottoli P, Castrogiovanni P. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008 Sep-Oct;30(5):441-5. doi: 10.1016/j.genhosppsych.2008.04.010. Epub 2008 Jul 23.
[PMID: 18774427] [DOI: 10.1016/j.genhosppsych.2008.04.010]
15) , 72) , 141)
Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol. 1997 Oct;32(10):1013-21. doi: 10.3109/00365529709011218.
[PMID: 9361174] [DOI: 10.3109/00365529709011218]
18) , 75)
Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry. 1998;59 Suppl 8:11-4; discussion 15-6.
[PMID: 9707157]
19) , 30)
Ortega AN, Huertas SE, Canino G, Ramirez R, Rubio-Stipec M. Childhood asthma, chronic illness, and psychiatric disorders. J Nerv Ment Dis. 2002 May;190(5):275-81. doi: 10.1097/00005053-200205000-00001.
[PMID: 12011605] [DOI: 10.1097/00005053-200205000-00001]
20) , 77) , 148) , 150)
Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord. 2001 May;16(3):507-10. doi: 10.1002/mds.1099.
[PMID: 11391746] [DOI: 10.1002/mds.1099]
21) , 51) , 107) , 155)
Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007 Nov-Dec;25(6):529-34. doi: 10.1016/j.clindermatol.2007.08.006.
[PMID: 18021889] [DOI: 10.1016/j.clindermatol.2007.08.006]
23) , 34) , 35) , 36) , 109) , 110) , 111) , 112)
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005 Sep;129(3):827-36. doi: 10.1053/j.gastro.2005.06.021.
[PMID: 16143122] [DOI: 10.1053/j.gastro.2005.06.021]
25) , 37) , 46) , 57) , 59) , 90) , 146)
Adams RJ, Wilson DH, Taylor AW, Daly A, Tursan d'Espaignet E, Dal Grande E, Ruffin RE. Coexistent chronic conditions and asthma quality of life: a population-based study. Chest. 2006 Feb;129(2):285-291. doi: 10.1378/chest.129.2.285.
[PMID: 16478843] [DOI: 10.1378/chest.129.2.285]
26) , 120) , 176)
Mihailova D, Grigorova R, Vassileva B, Mladenova G, Ivanova N, Stephanov S, Lissitchky K, Dimova E. Autoimmune thyroid disorders in juvenile chronic arthritis and systemic lupus erythematosus. Adv Exp Med Biol. 1999;455:55-60. doi: 10.1007/978-1-4615-4857-7_8.
[PMID: 10599323] [DOI: 10.1007/978-1-4615-4857-7_8]
27) , 39) , 47) , 62) , 65) , 94)
Caughey GE, Vitry AI, Gilbert AL, Roughead EE. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008 Jun 27;8:221. doi: 10.1186/1471-2458-8-221.
[PMID: 18582390] [PMCID: 2474682] [DOI: 10.1186/1471-2458-8-221]
29) , 105) , 125) , 154) , 159)
Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol. 2007 Jul;102(7):1429-35. doi: 10.1111/j.1572-0241.2007.01215.x. Epub 2007 Apr 16.
[PMID: 17437504] [DOI: 10.1111/j.1572-0241.2007.01215.x]
31) , 76)
Goodwin RD, Olfson M, Shea S, Lantigua RA, Carrasquilo O, Gameroff MJ, Weissman MM. Asthma and mental disorders in primary care. Gen Hosp Psychiatry. 2003 Nov-Dec;25(6):479-83. doi: 10.1016/s0163-8343(03)00071-9.
[PMID: 14706414] [DOI: 10.1016/s0163-8343(03)00071-9]
32) , 136)
Hasler G, Gergen PJ, Ajdacic V, Gamma A, Eich D, Rössler W, Angst J. Asthma and body weight change: a 20-year prospective community study of young adults. Int J Obes (Lond). 2006 Jul;30(7):1111-8. doi: 10.1038/sj.ijo.0803215. Epub 2006 Feb 21.
[PMID: 16491113] [DOI: 10.1038/sj.ijo.0803215]
33) , 137)
Gennuso J, Epstein LH, Paluch RA, Cerny F. The relationship between asthma and obesity in urban minority children and adolescents. Arch Pediatr Adolesc Med. 1998 Dec;152(12):1197-200. doi: 10.1001/archpedi.152.12.1197.
[PMID: 9856429] [DOI: 10.1001/archpedi.152.12.1197]
38) , 85)
Goldney RD, Ruffin R, Fisher LJ, Wilson DH. Asthma symptoms associated with depression and lower quality of life: a population survey. Med J Aust. 2003 May 5;178(9):437-41. doi: 10.5694/j.1326-5377.2003.tb05408.x.
[PMID: 12720509] [DOI: 10.5694/j.1326-5377.2003.tb05408.x]
40) , 138)
Perugi G, Akiskal HS, Pfanner C, Presta S, Gemignani A, Milanfranchi A, Lensi P, Ravagli S, Cassano GB. The clinical impact of bipolar and unipolar affective comorbidity on obsessive-compulsive disorder. J Affect Disord. 1997 Oct;46(1):15-23. doi: 10.1016/s0165-0327(97)00075-x.
[PMID: 9387083] [DOI: 10.1016/s0165-0327(97)00075-x]
43) , 81) , 134)
McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004 May;65(5):634-51, quiz 730. doi: 10.4088/jcp.v65n0507.
[PMID: 15163249] [DOI: 10.4088/jcp.v65n0507]
44) , 54) , 82)
Krishnan KRR, Delong M, Kraemer H, Carney R, Spiegel D, Gordon C, McDonald W, Dew M, Alexopoulos G, Buckwalter K, Cohen PD, Evans D, Kaufmann PG, Olin J, Otey E, Wainscott C. Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry. 2002 Sep 15;52(6):559-88. doi: 10.1016/s0006-3223(02)01472-5.
[PMID: 12361669] [DOI: 10.1016/s0006-3223(02)01472-5]
45) , 115)
Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TIA. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005 Dec;100(12):2724-9. doi: 10.1111/j.1572-0241.2005.00287.x.
[PMID: 16393226] [DOI: 10.1111/j.1572-0241.2005.00287.x]
48) , 164)
Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005 Dec;150(6):1115-21. doi: 10.1016/j.ahj.2005.02.007.
[PMID: 16338246] [DOI: 10.1016/j.ahj.2005.02.007]
49) , 165)
Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004 Nov;49(11):753-60. doi: 10.1177/070674370404901106.
[PMID: 15633853] [DOI: 10.1177/070674370404901106]
50) , 147)
Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum. 2001 Jun;30(6):436-43. doi: 10.1053/sarh.2001.23498.
[PMID: 11404827] [DOI: 10.1053/sarh.2001.23498]
52) , 70) , 89) , 104) , 144)
Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008 May 1;5(4):549-55. doi: 10.1513/pats.200709-148ET.
[PMID: 18453370] [PMCID: 2645334] [DOI: 10.1513/pats.200709-148ET]
53) , 152)
Gotsman I, Lotan C, Soskolne WA, Rassovsky S, Pugatsch T, Lapidus L, Novikov Y, Masrawa S, Stabholz A. Periodontal destruction is associated with coronary artery disease and periodontal infection with acute coronary syndrome. J Periodontol. 2007 May;78(5):849-58. doi: 10.1902/jop.2007.060301.
[PMID: 17470018] [DOI: 10.1902/jop.2007.060301]
55) , 83)
Parker G, Heruc G, Hilton T, Olley A, Brotchie H, Hadzi-Pavlovic D, Owen C, Friend C, Walsh WF. Explicating links between acute coronary syndrome and depression: study design and methods. Aust N Z J Psychiatry. 2006 Mar;40(3):245-52. doi: 10.1080/j.1440-1614.2006.01781.x.
[PMID: 16476152] [DOI: 10.1080/j.1440-1614.2006.01781.x]
56) , 84)
Stafford L, Berk M, Reddy P, Jackson HJ. Comorbid depression and health-related quality of life in patients with coronary artery disease. J Psychosom Res. 2007 Apr;62(4):401-10. doi: 10.1016/j.jpsychores.2006.12.009.
[PMID: 17383491] [DOI: 10.1016/j.jpsychores.2006.12.009]
60) , 87)
Burvill P, Johnson G, Jamrozik K, Anderson C, Stewart-Wynne E. Risk factors for post-stroke depression. Int J Geriatr Psychiatry. 1997 Feb;12(2):219-26. doi: 10.1002/(sici)1099-1166(199702)12:2<219::aid-gps581>3.0.co;2-e.
[PMID: 9097215] [DOI: 10.1002/(sici)1099-1166(199702)12:2<219::aid-gps581>3.0.co;2-e]
61) , 92)
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006 Jan 14;332(7533):73-8. doi: 10.1136/bmj.38678.389583.7C. Epub 2005 Dec 21.
[PMID: 16371403] [PMCID: 1326926] [DOI: 10.1136/bmj.38678.389583.7C]
63) , 64) , 96) , 173)
Fasano A. Systemic autoimmune disorders in celiac disease. Curr Opin Gastroenterol. 2006 Nov;22(6):674-9. doi: 10.1097/01.mog.0000245543.72537.9e.
[PMID: 17053448] [DOI: 10.1097/01.mog.0000245543.72537.9e]
67) , 68) , 99) , 100) , 106)
Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000 Jan 24;160(2):221-7. doi: 10.1001/archinte.160.2.221.
[PMID: 10647761] [DOI: 10.1001/archinte.160.2.221]
74) , 124)
Caccappolo-van Vliet E, Kelly-McNeil K, Natelson B, Kipen H, Fiedler N. Anxiety sensitivity and depression in multiple chemical sensitivities and asthma. J Occup Environ Med. 2002 Oct;44(10):890-901. doi: 10.1097/00043764-200210000-00006.
[PMID: 12391767] [DOI: 10.1097/00043764-200210000-00006]
78) , 149)
Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993 Oct 1;34(7):465-70. doi: 10.1016/0006-3223(93)90237-8.
[PMID: 8268331] [DOI: 10.1016/0006-3223(93)90237-8]
79) , 156)
Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol. 1993 Mar;32(3):188-90. doi: 10.1111/j.1365-4362.1993.tb02790.x.
[PMID: 8444530] [DOI: 10.1111/j.1365-4362.1993.tb02790.x]
86) , 91)
Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004 May;27(5):1066-70. doi: 10.2337/diacare.27.5.1066.
[PMID: 15111522] [DOI: 10.2337/diacare.27.5.1066]
88) , 103) , 135) , 157)
McNeely MJ, Boyko EJ. Diabetes-related comorbidities in Asian Americans: results of a national health survey. J Diabetes Complications. 2005 Mar-Apr;19(2):101-6. doi: 10.1016/j.jdiacomp.2004.08.003.
[PMID: 15745840] [DOI: 10.1016/j.jdiacomp.2004.08.003]
93) , 114)
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm Bowel Dis. 2007 Feb;13(2):225-34. doi: 10.1002/ibd.20062.
[PMID: 17206706] [DOI: 10.1002/ibd.20062]
98) , 151)
Emrich LJ, Shlossman M, Genco RJ. Periodontal disease in non-insulin-dependent diabetes mellitus. J Periodontol. 1991 Feb;62(2):123-31. doi: 10.1902/jop.1991.62.2.123.
[PMID: 2027060] [DOI: 10.1902/jop.1991.62.2.123]
101) , 122)
Paradowski B, Koszewicz M, Grodzicka I. [Chronic demyelinative polyneuropathy Guillain-Barré type in the course of systemic lupus erythematosus ]. Pol Merkur Lekarski. 2001 Feb;10(56):105-6.
[PMID: 11320574]
108) , 126)
Kimura K, Hunter SF, Thollander MS, Loftus EVJ, Melton LJ3, O'Brien PC, Rodriguez M, Phillips SF. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000 Aug;75(8):802-6. doi: 10.4065/75.8.802.
[PMID: 10943233] [DOI: 10.4065/75.8.802]
116) , 145)
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin Y, Yang H, Hewison M, Adams JS. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004 Aug;53(8):1129-36. doi: 10.1136/gut.2003.036657.
[PMID: 15247180] [PMCID: 1774134] [DOI: 10.1136/gut.2003.036657]
117) , 180)
Johnson LA, Wirostko E, Wirostko WJ. Crohn's disease uveitis. Parasitization of vitreous leukocytes by mollicute-like organisms. Am J Clin Pathol. 1989 Mar;91(3):259-64. doi: 10.1093/ajcp/91.3.259.
[PMID: 2923094] [DOI: 10.1093/ajcp/91.3.259]
119) , 143)
Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Chadha AB, Ramsey-Goldman R. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford). 2006 Jan;45(1):53-60. doi: 10.1093/rheumatology/kei079. Epub 2005 Nov 8.
[PMID: 16278288] [DOI: 10.1093/rheumatology/kei079]
121) , 170) , 177)
Scofield RH. Autoimmune thyroid disease in systemic lupus erythematosus and Sjögren's syndrome. Clin Exp Rheumatol. 1996 May-Jun;14(3):321-30.
[PMID: 8809450]
127) , 174)
Sloka JS, Phillips PEM, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis. 2005 Nov 9;2:9. doi: 10.1186/1740-2557-2-9.
[PMID: 16280086] [PMCID: 1308850] [DOI: 10.1186/1740-2557-2-9]
128) , 175)
Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology. 1999 Sep 11;53(4):883-5. doi: 10.1212/wnl.53.4.883.
[PMID: 10489063] [DOI: 10.1212/wnl.53.4.883]
129) , 168)
Sandberg-Wollheim M, Axéll T, Hansen BU, Henricsson V, Ingesson E, Jacobsson L, Larsson A, Lieberkind K, Manthorpe R. Primary Sjögren's syndrome in patients with multiple sclerosis. Neurology. 1992 Apr;42(4):845-7. doi: 10.1212/wnl.42.4.845.
[PMID: 1565240] [DOI: 10.1212/wnl.42.4.845]
130) , 169)
Miró J, Peña-Sagredo JL, Berciano J, Insúa S, Leno C, Velarde R. Prevalence of primary Sjögren's syndrome in patients with multiple sclerosis. Ann Neurol. 1990 May;27(5):582-4. doi: 10.1002/ana.410270522.
[PMID: 2136584] [DOI: 10.1002/ana.410270522]
140) , 166)
Tibbo P, Kroetsch M, Chue P, Warneke L. Obsessive-compulsive disorder in schizophrenia. J Psychiatr Res. 2000 Mar-Apr;34(2):139-46. doi: 10.1016/s0022-3956(99)00048-5.
[PMID: 10758256] [DOI: 10.1016/s0022-3956(99)00048-5]
182)
Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--multimorbidity. JAMA. 2012 Jun 20;307(23):2493-4. doi: 10.1001/jama.2012.5265.
[PMID: 22797447] [PMCID: 4083627] [DOI: 10.1001/jama.2012.5265]
183)
Weiss CO, Boyd CM, Yu Q, Wolff JL, Leff B. Patterns of prevalent major chronic disease among older adults in the United States. JAMA. 2007 Sep 12;298(10):1160-2. doi: 10.1001/jama.298.10.1160-b.
[PMID: 17848649] [DOI: 10.1001/jama.298.10.1160-b]
184) , 185)
Anderson G. (2010). Chronic care: making the case for ongoing care. Princeton, NJ: Robert Wood Johnson Foundation.
187)
Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull. 1996;22(3):413-30. doi: 10.1093/schbul/22.3.413.
[PMID: 8873293] [DOI: 10.1093/schbul/22.3.413]
188)
Pelczyńska M, Grzelak T, Sperling M, Bogdański P, Pupek-Musialik D, Czyżewska K. Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components. Arch Med Sci. 2017 Jun;13(4):745-752. doi: 10.5114/aoms.2016.58594. Epub 2016 Mar 16.
[PMID: 28721141] [PMCID: 5510509] [DOI: 10.5114/aoms.2016.58594]
189)
Syntax error [pubmed plugin]
190)
Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016 Oct 21;4(4):e1251384. doi: 10.1080/21688370.2016.1251384. eCollection 2016.
[PMID: 28123927] [PMCID: 5214347] [DOI: 10.1080/21688370.2016.1251384]
191)
Gardner JW, Gibbons RV, Hooper TI, Cunnion SO, Kroenke K, Gackstetter GD. Identifying new diseases and their causes: the dilemma of illnesses in Gulf War veterans. Mil Med. 2003 Mar;168(3):186-93.
[PMID: 12685682]
192)
Kassirer JP. Our stubborn quest for diagnostic certainty. A cause of excessive testing. N Engl J Med. 1989 Jun 1;320(22):1489-91. doi: 10.1056/NEJM198906013202211.
[PMID: 2497349] [DOI: 10.1056/NEJM198906013202211]
193)
Johnson HA. Diminishing returns on the road to diagnostic certainty. JAMA. 1991 May 1;265(17):2229-31.
[PMID: 1901611]
194)
Thwaites GE, Gant V. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?. Nat Rev Microbiol. 2011 Mar;9(3):215-22. doi: 10.1038/nrmicro2508. Epub 2011 Feb 7.
[PMID: 21297670] [DOI: 10.1038/nrmicro2508]
195)
Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol. 2011 Nov 2;11:244. doi: 10.1186/1471-2180-11-244.
[PMID: 22047020] [PMCID: 3228714] [DOI: 10.1186/1471-2180-11-244]
196)
Kuczynski J, Costello EK, Nemergut DR, Zaneveld J, Lauber CL, Knights D, Koren O, Fierer N, Kelley ST, Ley RE, Gordon JI, Knight R. Direct sequencing of the human microbiome readily reveals community differences. Genome Biol. 2010;11(5):210. doi: 10.1186/gb-2010-11-5-210. Epub 2010 May 5.
[PMID: 20441597] [PMCID: 2898070] [DOI: 10.1186/gb-2010-11-5-210]
197)
Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Knights D, Gajer P, Ravel J, Fierer N, Gordon JI, Knight R. Moving pictures of the human microbiome. Genome Biol. 2011;12(5):R50. doi: 10.1186/gb-2011-12-5-r50.
[PMID: 21624126] [PMCID: 3271711] [DOI: 10.1186/gb-2011-12-5-r50]